ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Eisai's new Alzheimer's drug divides market watchers

Leqembi's price point spurs optimism after Aduhelm, but wide use unclear

The success of Leqembi, developed by Eisai and Biogen, depends on the availability of tests needed for its prescription and other factors. (Photo courtesy of Eisai)

TOKYO -- Analysts are split on the outlook for Japanese drugmaker Eisai's new Alzheimer's treatment, with questions remaining over how many hospitals will have the diagnostic capabilities needed to administer it.

Lecanemab, developed with American partner Biogen, received fast-track approval from the U.S. Food and Drug Administration on Jan. 7. Eisai CEO Haruo Naito estimates that 100,000 American patients will be eligible for the drug in three years.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more